主页 > 医学前沿 >
【J Clin Oncol】美国临床肿瘤学会的临床实践指导
The American Society of Clinical Oncology (ASCO) published its first clinical practice guideline, which focused on the use of hematopoietic colony-stimulating factors, in 1994. Since then, ASCO has published 24 additional guidelines or technology assessments on a range of topics and is developing 11 additional guidelines. Guidelines are among ASCO's most valued products, according to membership surveys and data from the JCO.org Web site. However, the same data from ASCO members have highlighted a number of limitations to the guideline program. These relate to the timelines of guideline updates, difficulties locating guidelines and related products, and challenges to implementing ASCO guidelines in everyday clinical practice. This article outlines the concrete steps that the ASCO Health Services Committee (HSC) is taking to address these limitations, including the institution of a more aggressive guideline updating schedule, a transition from narrative to systematic literature reviews to support the practice recommendations, a new Board of Directors–approved policy to permit endorsement of other groups’ guidelines, and a robust Clinical Tools and Resources program that offers a range of guideline dissemination and implementation aids. Additional work is underway to establish stronger and deeper collaborations with practicing oncologists to expand their role in the review, field testing, and implementation of guideline clinical tools and resources. Finally, the HSC is discussing evaluation of the guidelines program to maximize the impact of ASCO clinical practice guidelines on clinical decision making and, ultimately, the quality of cancer care.
http://jco.ascopubs.org/cgi/content/abstract/26/24/4022 我认领本文翻译任务，若48小时内未完成，请其他战友随意 American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges
美国临床肿瘤学协会临床实践指南：机遇与挑战
The American Society of Clinical Oncology (ASCO) published its first clinical practice guideline, which focused on the use of hematopoietic colony-stimulating factors, in 1994. Since then, ASCO has published 24 additional guidelines or technology assessments on a range of topics and is developing 11 additional guidelines. Guidelines are among ASCO's most valued products, according to membership surveys and data from the JCO.org Web site. However, the same data from ASCO members have highlighted a number of limitations to the guideline program. These relate to the timelines of guideline updates, difficulties locating guidelines and related products, and challenges to implementing ASCO guidelines in everyday clinical practice. This article outlines the concrete steps that the ASCO Health Services Committee (HSC) is taking to address these limitations, including the institution of a more aggressive guideline updating schedule, a transition from narrative to systematic literature reviews to support the practice recommendations, a new Board of Directors–approved policy to permit endorsement of other groups’ guidelines, and a robust Clinical Tools and Resources program that offers a range of guideline dissemination and implementation aids. Additional work is underway to establish stronger and deeper collaborations with practicing oncologists to expand their role in the review, field testing, and implementation of guideline clinical tools and resources. Finally, the HSC is discussing evaluation of the guidelines program to maximize the impact of ASCO clinical practice guidelines on clinical decision making and, ultimately, the quality of cancer care.
美国临床肿瘤学协会（ASCO）在1994年公布其第一个临床实践的指南，重点是针对使用造血细胞集落刺激因子。自那时以来， ASCO就一系列议题已出版24个额外的指南或技术评估，并正在准备11个额外的指南。根据会员的调查和数据从JCO.org网站调查，指南是ASCO最有价值的产品。然而，从ASCO成员得出的同样数据突出了指南的若干不足。这涉及到指南更新的时间表，指导方针和相关产品定位的困难，在日常临床实践中落实ASCO指南的挑战。本文概述了ASCO保健服务委员会（HSC）正在为解决这些不足所采取得具体步骤：包括机构更积极的指南更新时间表，从对支持的措施、建议的叙事性描述到系统性地综述评论的过渡，新的通过的政策，允许通过同其他团体的指南交流，使强大的临床工具和资源计划用以形成提供了一系列指引、宣传和帮助。额外的工作正在进行中，用以与肿瘤工作实践建立更强和更深入的合作，以扩大其在检讨过程中进行实地测试并执行指引的临床工具和资源中的作用。最后，HSC正讨论指南的价值，在ASCO临床实践指南对临床决策计划发挥最大的影响，并最终对于癌症治疗结果的影响。 [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-24 05:34
医学,生命科学网